Orforglipron is a daily oral GLP-1 receptor agonist from Eli Lilly, authorised for use in the UK in August 2026. The MHRA decision made the UK the first country in Europe to approve it.
It belongs to the same broad family as semaglutide and tirzepatide — medicines that act on appetite regulation through GLP-1 signalling — but it is a small molecule rather than a peptide. That chemistry is the interesting part.
Why the Chemistry Matters
Peptide medicines like semaglutide are fragile. They are typically injected, and the oral version needs an absorption enhancer plus strict timing rules to survive the stomach. A small molecule does not have that problem in the same way, which in principle means simpler dosing and simpler manufacturing.
Simpler manufacturing is also the reason there is cautious optimism about supply. The weight-loss market in the UK has been shaped repeatedly by shortage — patients unable to get their dose, pharmacies prioritising existing customers, prices moving on availability rather than demand. A medicine that is easier to produce at scale is a different kind of proposition.
What We Do Not Know Yet
Being honest about the gaps is more useful than filling them:
- UK pricing has not settled. A recent authorisation is not a market price. Early figures from any single provider tell you very little.
- NHS availability follows a separate NICE process, and approval by the MHRA does not imply funding.
- Long-term real-world data in UK patients does not exist yet, by definition.
- Comparative effectiveness against established options in routine practice, as opposed to trial conditions, will take time to establish.
Side Effects
As a GLP-1 medicine, the expected profile is gastrointestinal — nausea, vomiting, diarrhoea, constipation — most pronounced when starting or increasing the dose. The MHRA's 2026 guidance on severe acute pancreatitis with GLP-1 medicines is relevant here as it is across the class: severe, persistent abdominal pain radiating to the back warrants urgent assessment.
Anyone taking a newly authorised medicine has a particular reason to report suspected side effects through the Yellow Card scheme. Post-authorisation reporting is how the safety picture for a new medicine actually gets built.
Should You Wait for It?
If you are currently untreated and considering starting, "wait for the new thing" is usually poor advice — the treatment that exists and that your prescriber can supply today has a known profile and a known price.
If you are already established on something that works for you, a new arrival is not a reason to switch. Novelty is not efficacy.
Where orforglipron may genuinely matter is downstream: more options in a market tends to loosen pricing, and this market has been unusually tight. That is worth watching, and it is worth watching across providers rather than at one.